PDE5
11 drugs Cardiovascular
2
approved indications
11
Approved Drugs
10
Companies
3
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (10 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (3 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Eli Lilly 2 drugs
Aurobindo Pharma 1 drug
ZYDUS PHARMS 1 drug
By Therapeutic Area
Other 7 drugs
Cardiovascular 4 drugs
Drugs by Company PRO
By Therapeutic Area
Other 7 drugs
TADALAFIL, CIALIS, VARDENAFIL HYDROCHLORIDE, VIAGRA +3 more
Cardiovascular 4 drugs
ALYQ, TADLIQ, OPSYNVI, ADCIRCA
Indications Treated
Erectile DysfunctionBenign Prostatic HyperplasiaPulmonary Arterial Hypertension
All Drugs Targeting PDE5
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| TADALAFIL | Aurobindo Pharma | 2018 | 2 | |
| CIALIS | Eli Lilly | 2003 | 2 | |
| VARDENAFIL HYDROCHLORIDE | ZYDUS PHARMS | 2012 | 1 | |
| VIAGRA | Viatris | 1998 | 1 | |
| ALYQ | Teva | 2019 | 1 | Cardiovascular |
| VYBRIQUE | IBSA | 2025 | 1 | |
| TADLIQ | CMP DEV LLC | 2022 | 1 | Cardiovascular |
| OPSYNVI | ACTELION | 2024 | 1 | Cardiovascular |
| AVANAFIL | HETERO LABS LTD V | 2024 | 1 | |
| STENDRA | VIVUS LLC | 2012 | 1 | |
| ADCIRCA | Eli Lilly | 2009 | 1 | Cardiovascular |